Max Planck Institute to award Miodownik medal for science communication
Plaudits continue to flow for UCL Professor of Materials and Society, Mark Miodownik, as the Max Planck Institute for Biophysical Chemistry is set to…Read more
The novel transcatheter aortic valve developed at UCL, was for the first time implanted in an ovine model (about 50 kg) on the 29th of May 2013, by Mike Mullen and John Yap (UCLH Heart Hospital), at IMM Recherche, Paris. The valve was collapsed in the delivery system and successfully implanted off-pump via brachiocephalic approach in orthotopic position, using continuous ultrasonic and fluoroscopic guidance.
Dr Mullen successfully implanted and extracted three valves of different sizes (23 mm, 26 mm and 29 mm). Each valve was retrieved into the catheter and repositioned, after assessing their optimal positioning and hemodynamic performance. No interference of coronary blood flow was observed for the two smallest sizes, more suitable for the animal anatomy, and good acute valve function with no significant regurgitation was confirmed for all devices.
The first preclinical in vivo trial has confirmed the unique features of the device, developed from a multidisciplinary collaboration between the UCL Department of Mechanical Engineering (Dr G Burriesci – Project Leader – and his team), the UCL Centre for Nanotechnology & Regenerative Medicine (Prof A Seifalian’s group) and The Heart Hospital UCLH (Dr M Mullen and Mr J Yap), with the support of the Wellcome Trust.
Last modified on